169 related articles for article (PubMed ID: 9435912)
1. Azinyl and diazinyl hydrazones derived from aryl N-heteroaryl ketones: synthesis and antiproliferative activity.
Easmon J; Heinisch G; Pürstinger G; Langer T; Osterreicher JK; Grunicke HH; Hofmann J
J Med Chem; 1997 Dec; 40(26):4420-5. PubMed ID: 9435912
[TBL] [Abstract][Full Text] [Related]
2. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
Klutchko SR; Hamby JM; Boschelli DH; Wu Z; Kraker AJ; Amar AM; Hartl BG; Shen C; Klohs WD; Steinkampf RW; Driscoll DL; Nelson JM; Elliott WL; Roberts BJ; Stoner CL; Vincent PW; Dykes DJ; Panek RL; Lu GH; Major TC; Dahring TK; Hallak H; Bradford LA; Showalter HD; Doherty AM
J Med Chem; 1998 Aug; 41(17):3276-92. PubMed ID: 9703473
[TBL] [Abstract][Full Text] [Related]
3. Substituted 2-acylpyridine-alpha-(N)-hetarylhydrazones as inhibitors of ribonucleotide reductase activity and L1210 cell growth.
Cory JG; Downes DL; Cory AH; Schaper KJ; Seydel JK
Anticancer Res; 1994; 14(3A):875-9. PubMed ID: 8074487
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (Ara-C) and induction of cellular apoptosis.
Nandy P; Lien EJ; Avramis VI
Anticancer Res; 1999; 19(3A):1625-33. PubMed ID: 10470093
[TBL] [Abstract][Full Text] [Related]
5. Ribose-modified purine nucleosides as ribonucleotide reductase inhibitors. Synthesis, antitumor activity, and molecular modeling of N6-substituted 3'-C-methyladenosine derivatives.
Cappellacci L; Franchetti P; Vita P; Petrelli R; Lavecchia A; Jayaram HN; Saiko P; Graser G; Szekeres T; Grifantini M
J Med Chem; 2008 Jul; 51(14):4260-9. PubMed ID: 18588281
[TBL] [Abstract][Full Text] [Related]
6. Antiproliferative action of isatine-beta-thiocarbohydrazone and N-ethylisatine-beta-thiocarbohydrazone on human PBMC and on two neoplastic cell lines.
Juranić Z; Anastasova F; Juranić I; Stanojković T; Radulović S; Vuletić N
J Exp Clin Cancer Res; 1999 Sep; 18(3):317-24. PubMed ID: 10606176
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, cytotoxic, and antitumor activities of 2-pyridylhydrazones derived from 3-benzoylpyridazines.
Easmon J; Pürstinger G; Heinisch G; Fiebig HH; Roth T; Hofmann J
Arch Pharm (Weinheim); 2014 Aug; 347(8):599-608. PubMed ID: 24917378
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and antiproliferative activity of benzo[d]isothiazole hydrazones.
Vicini P; Incerti M; Doytchinova IA; La Colla P; Busonera B; Loddo R
Eur J Med Chem; 2006 May; 41(5):624-32. PubMed ID: 16540208
[TBL] [Abstract][Full Text] [Related]
9. Structural study of ribonucleotide reductase inhibitor hydrazones. Synthesis and X-ray diffraction analysis of a copper(II)-benzoylpyridine-2-quinolinyl hydrazone complex.
Tamasi G; Chiasserini L; Savini L; Sega A; Cini R
J Inorg Biochem; 2005 Jun; 99(6):1347-59. PubMed ID: 15869799
[TBL] [Abstract][Full Text] [Related]
10. Homonojirimycin isomers and N-alkylated homonojirimycins: structural and conformational basis of inhibition of glycosidases.
Asano N; Nishida M; Kato A; Kizu H; Matsui K; Shimada Y; Itoh T; Baba M; Watson AA; Nash RJ; Lilley PM; Watkin DJ; Fleet GW
J Med Chem; 1998 Jul; 41(14):2565-71. PubMed ID: 9651160
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, structure-activity relationships, and antitumor studies of 2-benzoxazolyl hydrazones derived from alpha-(N)-acyl heteroaromatics.
Easmon J; Pürstinger G; Thies KS; Heinisch G; Hofmann J
J Med Chem; 2006 Oct; 49(21):6343-50. PubMed ID: 17034140
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and antiproliferative activity of aryl- and heteroaryl-hydrazones derived from xanthone carbaldehydes.
Varache-Lembège M; Moreau S; Larrouture S; Montaudon D; Robert J; Nuhrich A
Eur J Med Chem; 2008 Jun; 43(6):1336-43. PubMed ID: 17949859
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of malignant cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class: effect on the R2 subunit of ribonucleotide reductase.
Green DA; Antholine WE; Wong SJ; Richardson DR; Chitambar CR
Clin Cancer Res; 2001 Nov; 7(11):3574-9. PubMed ID: 11705879
[TBL] [Abstract][Full Text] [Related]
14. New alpha-(N)-heterocyclichydrazones: evaluation of anticancer, anti-HIV and antimicrobial activity.
Savini L; Chiasserini L; Travagli V; Pellerano C; Novellino E; Cosentino S; Pisano MB
Eur J Med Chem; 2004 Feb; 39(2):113-22. PubMed ID: 14987820
[TBL] [Abstract][Full Text] [Related]
15. Hydrazones of 2-aryl-quinoline-4-carboxylic acid hydrazides: synthesis and preliminary evaluation as antimicrobial agents.
Metwally KA; Abdel-Aziz LM; Lashine el-SM; Husseiny MI; Badawy RH
Bioorg Med Chem; 2006 Dec; 14(24):8675-82. PubMed ID: 16949294
[TBL] [Abstract][Full Text] [Related]
16. Characterization of mouse leukemia L1210 cells resistant to the ribonucleotide reductase inhibitor 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
Cory AH; Sato A; Thompson DP; Cory JG
Oncol Res; 1996; 8(10-11):449-56. PubMed ID: 9114437
[TBL] [Abstract][Full Text] [Related]
17. Chelating agents as potential antitumorals: alpha-(N)-heterocyclic hydrazones and bis-alpha-(N)-heterocyclic hydrazones.
Savini L; Massarelli P; Chiasserini L; Nencini C; Pellerano C
Farmaco; 1997 Oct; 52(10):609-13. PubMed ID: 9507672
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of 6-(dibromomethyl)-5-nitropyrimidines as potential antitumor agents.
Thompson MD; Cupps TL; Wise DS; Wotring LL; Townsend LB
J Med Chem; 1997 Feb; 40(5):766-70. PubMed ID: 9057863
[TBL] [Abstract][Full Text] [Related]
19. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 2. Effect of pyrrole-C2 and/or -C4 substitutions on biological activity.
Mai A; Massa S; Cerbara I; Valente S; Ragno R; Bottoni P; Scatena R; Loidl P; Brosch G
J Med Chem; 2004 Feb; 47(5):1098-109. PubMed ID: 14971890
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of 10-methanesulfonyl-DDACTHF, 10-methanesulfonyl-5-DACTHF, and 10-methylthio-DDACTHF as potent inhibitors of GAR Tfase and the de novo purine biosynthetic pathway.
Cheng H; Chong Y; Hwang I; Tavassoli A; Zhang Y; Wilson IA; Benkovic SJ; Boger DL
Bioorg Med Chem; 2005 May; 13(10):3577-85. PubMed ID: 15848770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
